11/01/2019 21:05:00

AXOGEN, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for Middle District of Florida against AxoGen, Inc.

NEW YORK, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a class action lawsuit has been filed in the United States District Court for Middle District of Florida against AxoGen, Inc. ("AxoGen" or the “Company") (NASDAQ: AXGN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AxoGen securities pursuant and/or traceable to

  • the Company’s registration statement and prospectus (collectively, the “November 2017 Registration Statement”) issued in connection with its November 2017 secondary public offering (“November SPO”); and/or


  • the Company’s false and/or misleading registration statement and prospectus (collectively, the “May 2018 Registration Statement”) issued in connection with the Company’s May 2018 secondary public offering (“May SPO”); and/or


  • between August 7, 2017 and December 18, 2018, inclusive (the “Class Period”).

Investors who have incurred losses in the shares of AxoGen, Inc. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If you have incurred losses in the shares ofAxoGen, Inc.,you may,no later than March 11, 2019, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in AxoGen, Inc.

The filed Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:

  • AxoGen aggressively increased prices to mask lower sales;


  • AxoGen’s pricing alienated customers and threatened the Company’s future growth;


  • ambulatory surgery centers form a significant part of the market for the Company’s products;


  • such centers were especially sensitive to price increases;


  • the Company was dependent on a small number of surgeons whom the Company paid to generate sales;


  • AxoGen’s consignment model for inventory was reasonably likely to lead to channel stuffing;


  • the Company offered purchase incentives to sales representatives to encourage channel stuffing;


  • the Company’s sales representatives were encouraged to backdate revenue to artificially inflate metrics;


  • the Company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue;


  • the Company’s key operating metrics, such as number of active accounts, were overstated; and


  • consequently, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
  • On December 18, 2018, Seligman Investments reported that “[a] number of former [AxoGen] employees allege channel stuffing [at AxoGen], given that the company’s consignment model creates potential for abuse, as well as alleging questionable revenue recognition practices.” The article continued to state that “allegations additionally include misleading operating metrics, with one former rep implying that the company’s definition of ‘active accounts’ may overstate the actual number by a factor of ten.”

    Following this news, AxoGen stock dropped $6.17 per share, or roughly 22%, to close at $21.36 on December 18, 2018.

    ## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

    Wolf Haldenstein Adler Freeman & Herz LLP

     has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

    If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.


    Wolf Haldenstein Adler Freeman & Herz LLP

    Kevin Cooper, Esq.

    Gregory Stone, Director of Case and Financial Analysis

    Email: gstone@whafh.comkcooper@whafh.com or classmember@whafh.com

    Tel: (800) 575-0735 or (212) 545-4774

    Attorney Advertising. Prior results do not guarantee or predict a similar outcome.


    Related content
    23 May - 
    Axogen, Inc. to Participate at Upcoming Investor Confer..
    08 May - 
    Axogen, Inc. Reports 2019 First Quarter Financial Resul..
    02 May - 
    Axogen, Inc. Appoints New Members to Board of Directors

    Post comment

    Related debate

    • 1 week
    • 1 month
    • 1 Year
    Ingen indlæg


    EuroInvestor: In Focus


    EuroInvestor: In Focus


    EuroInvestor: In Focus

    Most read news

    • 24 hours
    • 48 hours
    • 1 week
    uBreakiFix Expands Dallas Footprint With Grand Prairie Store
    Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
    Translate Bio Appoints George Demetri, M.D., to its Board of Directors
    Aemetis India Expands Revenues to $50 Million Per Year Run Rate Driven by Biodiesel Shipments to Large Refiners

    Related stock quotes

    AxoGen Inc 19.70 -3.7% Stock price decreasing

    Latest news

    Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
    Quote information is delivered by Morningstar.
    Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
    16 July 2019 01:52:29
    (UTC+00:00) Dublin, Edinburgh, Lisbon, London
    Version: LiveBranchBuild_20190703.1 - EUROWEB5 - 2019-07-16 02:52:29 - 2019-07-16 01:52:29 - 1000 - Website: OKAY